Tech Company Financing Transactions
Exeliom Biosciences Funding Round
CE Ventures, Auriga Partners and Biocodex joined a $8.9 million Series A capital raise for Exeliom Biosciences. The financing round was recorded on 7/20/2023.
Transaction Overview
Company Name
Announced On
7/20/2023
Transaction Type
Venture Equity
Amount
$8,862,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to progress the clinical development of its lead candidate EXL01 into two new therapeutic areas: immuno-oncology and infectious diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
67 Rue Des Godrans
Dijon, 21000
FR
Dijon, 21000
FR
Phone
Undisclosed
Website
Email Address
Overview
We develop novel therapies that modulate the immune-system in a non-suppressive manner. The fact that our drug candidates modulate, but do not suppress, the immune-system is what makes them more suited for chronic administration than currently available medicines, especially for the majority of patients who have mild to moderate symptoms. We source our drug candidates by studying and analyzing real-life observational human clinical trial data, in a non-systematic manner and without a priori. This pioneering translational human discovery first approach is what makes us and our programs so special.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Hadida
Co-Founder
Patrick Gervais
Co-Founder
Philippe Langella
Browse more venture capital transactions:
Prev: 7/20/2023: Whop venture capital transaction
Next: 7/20/2023: Cleanlab venture capital transaction
Share this article
Where The Data Comes From
We report on all VC transactions involving tech companies. VC transactions on this site come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs